Literature DB >> 29382645

First PARP Inhibitor Ok'd for Breast Cancer.

.   

Abstract

The FDA has approved olaparib, a PARP inhibitor, for use in patients with metastatic breast cancer who also carry a germline BRCA1 or BRCA2 mutation. With the January 12 approval, olaparib becomes the first targeted therapy for patients with breast cancer with mutated BRCA. ©2018 American Association for Cancer Research.

Entities:  

Year:  2018        PMID： 29382645     DOI： 10.1158/2159-8290.CD-NB2018-008

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  6 in total

1.  Development and MPI tracking of novel hypoxia-targeted theranostic exosomes.

Authors:  Kyung Oh Jung; Hunho Jo; Jung Ho Yu; Sanjiv Sam Gambhir; Guillem Pratx
Journal:  Biomaterials       Date:  2018-05-29       Impact factor: 12.479

2.  Real-World Use and Outcomes of Olaparib: a Population-Based Cohort Study.

Authors:  Irene Eriksson; Björn Wettermark; Kjell Bergfeldt
Journal:  Target Oncol       Date:  2018-12       Impact factor: 4.493

3.  BRCA1 and BRCA2 Gene Mutations and Lung Cancer Sisk: A Meta-Analysis.

Authors:  Yen-Chien Lee; Yang-Cheng Lee; Chung-Yi Li; Yen-Ling Lee; Bae-Ling Chen
Journal:  Medicina (Kaunas)       Date:  2020-04-27       Impact factor: 2.430

4.  The high expression of NUDT5 indicates poor prognosis of breast cancer by modulating AKT / Cyclin D signaling.

Authors:  He Zhang; Li-Qun Zhang; Cheng-Cheng Yang; Jin Li; Xin-Yuan Tian; Dan-Ni Li; Ju Cui; Jian-Ping Cai
Journal:  PLoS One       Date:  2021-02-11       Impact factor: 3.240

Review 5.  Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer.

Authors:  Chao Dong; Jiao Wu; Yin Chen; Jianyun Nie; Ceshi Chen
Journal:  Front Pharmacol       Date:  2021-03-15       Impact factor: 5.810

6.  Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibition.

Authors:  Rania El Botty; Florence Coussy; Rana Hatem; Franck Assayag; Sophie Chateau-Joubert; Jean-Luc Servely; Sophie Leboucher; Charles Fouillade; Sophie Vacher; Bérengère Ouine; Aurélie Cartier; Leanne de Koning; Paul Cottu; Ivan Bièche; Elisabetta Marangoni
Journal:  Oncotarget       Date:  2018-07-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.